
Investor relations
Company profile
SDS Optic S.A. develops innovative products for medical diagnostics. Its flagship project is inPROBE, a fiber-optic microsensor for oncology biomarker diagnostics.

See the latest financial report
Consolidated financial report for 2025
Periodic report EBI 17/2026 released on June 2, 2026
Learn more
Investor's calendar
Schedule of periodic report publications in 2026:
Quarterly report for Q4-2025 – February 12, 2026
Quarterly report for Q1-2026 – May 14, 2025
Quarterly report for Q2-2026 – August 13, 2026
Quarterly report for Q3-2026 – November 10, 2026
Annual report for 2025 – June 1, 2026

Contact for investors
Marketing, Communications and IR Team
+48 81 501 94 63ir@sdsoptic.comFrequently asked questionsStock quote
The company has been listed on the NewConnect market of the Warsaw Stock Exchange since March 15, 2022
Sector: medical equipment and supplies
ISIN: PLSDSO00013
Ticker: SDS
Learn more
SDS Optonic Sp. z o.o. is an entity controlled by Marcin Staniszewski, President of the Management Board of the Issuer. As of the date of publication of this report, he—together with his spouse and the financial shareholders of SDS Optonic Sp. z o.o.—holds a total of 2,643,860 shares in the Company, representing 39.61% of the Company’s share capital and conferring the right to exercise 2,643,860 votes at the General Meeting of the Issuer, i.e., 39.61% of the total number of votes in the Company. Marcin Staniszewski individually holds rights to 1,282,934 shares of the Issuer, representing 19.22% of the Company’s share capital. The remaining shareholders of SDS Optonic Sp. z o.o. are entitled to 1,147,826 shares of the Issuer, representing 17.9% of the Company’s share capital. According to the information available to the Company, Paweł Kania and Ewa Kania are spouses and, pursuant to Article 87(4)(1) of the Act on Public Offering, are presumed to be acting in concert with respect to holding shares in the Company and exercising voting rights attached to those shares. The total shareholding of the spouses acting in concert amounts to 681,200 shares, representing 10.20% of the Company’s share capital and conferring 10.20% of the total number of votes at the General Meeting. Of this amount, Paweł Kania directly holds 667,300 shares, representing 9.996% of the share capital and voting rights, while Ewa Kania directly holds 13,900 shares, representing 0.21% of the share capital and voting rights.

SDS Optic Group Capital Structure
As of the end of December 2024, SDS Optic S.A. is the parent company of two subsidiaries, FiBioMed Sp. z o.o. and SDS Optic Inc., in which it holds majority stakes
Authorized Advisor and Market Animator
Authorized Advisor

Navigator Capital S.A.
18 Twarda Street, Warsawbiuro@navigatorcapital.plhttps://navigatorcapital.pl/+48 22 630 83 33We Care About Your Privacy
SDS Optic S.A. uses cookies to improve and customize users experience on our website. By selecting 'Accept', you consent to the use of all cookies that gather and use information about your interactions with our site to provide personalized content and enhance your digital experience. Please read our Privacy Policy for more information.






